What changed in SF 296
The bill as introduced, compared with the version both chambers passed (89th General Assembly). 1 adopted amendment account for the changes.
0 passages reworded, 10 added and 26 removed; 8 of 44 unchanged.
Removed AddedIntroduced textText as passedAmendments
Compares wording only. The printed bills also mark changes to existing law with strikes and underlines, which aren’t shown here.
Section 1. Section 155A.46, Code 2021, is amended to read as follows: 155A.46 Statewide Administration of drugs —— statewide protocols.
1.
a. A pharmacist may, pursuant to statewide protocols developed by the board in consultation with the department of public health and consistent with subsection 2 3, order and administer the following to patients ages eighteen years and older:
(1) a. Naloxone.
(2) b. Nicotine replacement tobacco Tobacco cessation products.
c. Point-of-care testing and treatment for influenza, streptococcus A, and COVID-19 as defined in section 686D.2 at the point of interaction between a pharmacist and a patient.
d. Point-of-care testing at the point of interaction between a pharmacist and a patient in response to a public health emergency.
2.
a. A pharmacist may prescribe and administer the following to patients ages three years and older:
(3) (1) An immunization or vaccination recommended by the United States centers for disease control and prevention advisory committee on immunization practices in its approved vaccination schedule for adults.
(4) (2) An immunization or vaccination recommended by the United States centers for disease control and prevention for international travel.
(5) A Tdap (tetanus, diphtheria, acellular pertussis) vaccination in a booster application.
(3) Vaccines currently licensed for use in the United States on the list issued by the United States food and drug administration, including those related to COVID-19.
(6) (4) Other emergency immunizations or vaccinations in response to a public health emergency.
b. A pharmacist may, pursuant to statewide protocols developed by the board in consultation with the department of public health and consistent with subsection 2, order prescribe and administer the following to patients ages six months and older:
(1) A vaccine or An immunization or vaccination for influenza.
(2) Other emergency immunizations or vaccines vaccinations in response to a public health emergency.
c. A pharmacist may, pursuant to statewide protocols developed by the board in consultation with the department of public health and consistent with subsection 2, order and administer the final two doses in a course of vaccinations for HPV to patients ages eleven years and older.
d.
c. Prior to the ordering prescribing and administration of a vaccination or an immunization or vaccination authorized by this subsection, pursuant to statewide protocols, a licensed pharmacist shall consult and review the statewide immunization registry or health information network. The board shall adopt rules requiring the reporting of the administration of vaccines and immunizations and vaccinations authorized by this subsection to a patient’s primary health care provider, primary physician, and a statewide immunization registry or health information network.
2.
3. A pharmacist prescribing, ordering, or administering a prescription drug, product, test, or treatment pursuant to subsection 1 or 2 shall do all of the following:
a. Maintain a record of all prescription drugs, products, tests, and treatments administered pursuant to this section.
Section 1. Section 155A.46, subsection 1, paragraph a, Code 2021, is amended by adding the following new subparagraph:
b. Notify the patient’s primary health care provider of any prescription drugs, products, tests, or treatments administered to the patient, or enter such information in a patient record system also used by the primary health care provider, as permitted by the primary health care provider. If the patient does not have a primary health care provider, the pharmacist shall provide the patient with a written record of the prescription drugs, products, tests, or treatment provided to the patient and shall advise the patient to consult a physician.
NEW SUBPARAGRAPH.
c. Complete continuing pharmacy education related to statewide protocols and immunizations and vaccinations recognized and approved by the board.
(7) An immunization or vaccination for C0VID-19 as defined in section 686D.2.
Sec.
2. Section 155A.46, subsection 1, Code 2021, is amended by adding the following new paragraph:
NEW PARAGRAPH.
e. A pharmacist may, pursuant to statewide protocols developed by the board in consultation with the department of public health and consistent with subsection 2, order and administer the following to patients ages six years and older:
(1) Point-of-care testing and treatment for influenza, streptococcus A, and COVID-19 as defined in section 686D.2 at the point of interaction between a pharmacist and a patient.
(2) Point-of-care testing at the point of interaction between a pharmacist and a patient in response to a public health emergency.
Sec.
2.
3.
NEW SECTION. 155A.47 Collaborative pharmacy practice —— agreements —— payment.
5 unchanged passages
1. For the purposes of this section:
a. “Collaborative pharmacy practice” means a practice of pharmacy whereby a pharmacist provides patient care and drug therapy management services not otherwise permitted to be performed by a pharmacist to patients under a collaborative pharmacy practice agreement with another pharmacist or practitioner which defines the nature, scope, conditions, and limitations of the patient care and drug therapy management services to be provided by a pharmacist in order to ensure that a patient achieves the desired outcomes.
b. “Health benefit plan” means the same as defined in section 514J.102.
c. “Health carrier” means the same as defined in section 514J.102.
2. Notwithstanding any provision of law to the contrary, a pharmacist may engage in a collaborative pharmacy practice, in accordance with rules adopted by the board pursuant to chapter 17A and under a collaborative pharmacy practice agreement, to provide patient care and drug therapy management services to a patient.
3. Notwithstanding any provision of a health benefit plan to the contrary, whenever a health benefit plan provides for payment or reimbursement for a service that is within the lawful scope of practice of a practitioner or pharmacist and the service is provided by a pharmacist pursuant to a collaborative pharmacy practice agreement under this section, the health carrier may provide payment or reimbursement for the service.